MentalHealthDaily

Pharmacogenomics (PGx) for Depression: Genetic Analysis to Amplify Antidepressant Efficacy? (2023 Review)

by GLOOM

Depression, a leading cause of disability globally, often presents challenges in treatment due to the variability in individual responses to antidepressants. Pharmacogenomic (PGx) testing, an approach aligning treatment with genetic makeup, promises to tailor depression therapy more effectively. Highlights: Major Depressive Disorder (MDD) impacts a significant portion of the global population, with traditional treatments often …

Psilocybin for Major Depression in Adults (2023 Evidence Review)

by GLOOM

The emerging research into psilocybin, a classical psychedelic, reveals its significant potential in treating Major Depressive Disorder (MDD). Historically used in spiritual and shamanic practices, psilocybin’s recent clinical studies have opened new avenues in mental health treatment, challenging traditional antidepressants like SSRIs. Highlights: Psilocybin’s Historical & Clinical Relevance: A natural compound used for millennia, recent …

Esketamine Nasal Spray Effective Last Resort for Treatment-Resistant Depression (TRD)? (2023 Study)

by GLOOM

Treatment-resistant depression (TRD) represents a significant challenge in mental health care, often leaving patients and clinicians in a difficult position after traditional treatments fail. Recent studies, including a prospective, observational study at a leading medical center, have brought new hope in the form of esketamine, a novel antidepressant. Highlights: Esketamine’s Mechanism: Esketamine, the S-enantiomer of …

Top 10 Repurposed Drug Candidates for Bipolar Disorder Uncovered via Gene Network Analysis (2024 Study)

by GLOOM

Bipolar disorder (BD) remains a complex psychiatric condition with limited therapeutic options, posing a significant challenge in drug discovery. The latest research leverages network-based drug repurposing, employing advanced computational techniques to identify novel treatment strategies for bipolar disorder. Highlights: Network-based drug repurposing employs gene regulatory networks to identify potential new uses for existing drugs in …

Antidepressants & Dementia Risk in Elderly Users: SSRIs vs. TCAs (2024 Study)

by GLOOM

Recent research has uncovered connections between the use of antidepressants and the risk of developing dementia in the elderly. This complex relationship, marked by varying results and considerations, is becoming a critical area of study in geriatric medicine and mental health. In light of these findings, it is crucial to delve into the nuances of …

Evening Chronotype & Lower Efficacy of SSRI Antidepressants (2024 Study)

by GLOOM

Recent research in the Australian Genetics of Depression Study reveals a fascinating connection between an individual’s chronotype and the efficacy of antidepressants. A study, focusing on selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), suggests that evening chronotypes may experience poorer responses to these medications. Highlights: Chronotype Impact: Individuals with an evening chronotype reported …

Genetics of Tobacco Use Disorder (TUD) & Nicotine Addiction (2024 Study)

by GLOOM

Tobacco use is a complex behavior influenced by both environmental factors and genetic predispositions. A recent study leveraging the UCLA ATLAS biobank explored the genetic underpinnings of Tobacco Use Disorder (TUD) and its systemic health effects using a Polygenic Score (PGS). Highlights: Genetic Underpinnings of Tobacco Use: The study used a European ancestry-derived PGS to …